Keyphrases
Hemodialysis Patients
100%
Spironolactone
100%
Non-diabetic
100%
Carotid Intima-media Thickness (cIMT)
100%
Randomized Placebo-controlled Trial
100%
Placebo
55%
Plasma Potassium
33%
Randomized Controlled Trial
22%
Thrice Weekly
22%
Chronic Kidney Disease
11%
Coronary Artery Disease
11%
Dialysis
11%
No Significant Difference
11%
Thickness Measurement
11%
Hyperkalemia
11%
Cardiac Disease
11%
Cardiac Mortality
11%
Heart Failure
11%
Placebo Groups
11%
Common Carotid
11%
Dialysis Session
11%
Carotid Bifurcation
11%
Ultrasonographic Measurements
11%
Vascular Injury
11%
Heart Stroke
11%
Intervention Effectiveness
11%
Potassium Concentration
11%
Internal Carotid
11%
Progression Rate
11%
Medicine and Dentistry
Hemodialysis
100%
Placebo
100%
Intima-Media Thickness
100%
Spironolactone
100%
Randomized Controlled Trial
22%
Coronary Artery Disease
11%
Heart Disease
11%
Chronic Kidney Disease
11%
Apoplexy
11%
Heart Failure
11%
Blood Vessel Injury
11%
Hyperkalemia
11%
Pharmacology, Toxicology and Pharmaceutical Science
Hemodialysis
100%
Spironolactone
100%
Placebo
100%
Isotopes of Potassium
33%
Randomized Controlled Trial
22%
Chronic Kidney Failure
11%
Hyperkalemia
11%
Heart Disease
11%
Heart Failure
11%
Blood Vessel Injury
11%
Coronary Artery Disease
11%